In this online CME self-learning program:
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma (NHL), making up just under a third of NHL cases. In the United States, there are roughly 7 cases of DLBCL per 100,000 patients per year. The pathophysiology of DLBCL is complex and not fully understood; but is characterized by a widespread increase of very large, mature B-cells arising from various gene mutations. DLBCL is heterogenous group of tumors and includes many diverse subtypes based on location, presence of other cells within the tumor, and whether the patient has other related illnesses. Advanced age, immunodeficiency, and Epstein-Barr virus are associated risk factors for DLBCL. The disease is considered an AIDS-defining malignancy, marking the point at which an HIV infection is considered AIDS. Diagnosis of DLBCL is made by a tissue biopsy, and morphology and immunophenotyping play a crucial role in determining which subtype of DLBCL a patient has.
The following HCPs: Hematologists and oncologists; physician assistants, nurse practitioners, and pharmacists who practice in oncology; and any other HCPs with an interest in or who clinically encounter patients with DLBCL.
This program is supported by educational grants from Seattle Genetics.
This activity is free of charge.
Release Date: December 22, 2020 -- Expiration Date: December 22, 2022
Faculty: Carla Casulo, MD
Epidemiology and diagnosis of DLBCL
· The most affected: A demographic review
· Risk factors
· Clinical features, presentation, and pathophysiology
· Prognostic significance of phenotypic and cytogenetic features
· Patient case(s)
Management of DLBCL: Contemporary guidelines, agents, and monitoring
· Clinical considerations
· Germinal center vs. activated B cell types R-CHOP
· Double hit, double expressor
· First-line therapies and beyond
· Treatment mechanisms and toxicities
· Monitoring and outcomes
· Alternative approaches in special populations: elderly adults, coexistent with or with features intermediate to other lymphomas
· Complications and their management
· Investigational and emerging therapies
· Best practice and clinical pearls
· Patient cases
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #201718477
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Carla Casulo, MD, Assistant Professor, Department of Medicine, Division of Hematology and Oncology, University of Rochester, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME, has no relevant financial disclosures.
Commercial Support Disclosure: This program is supported by educational grants from Seattle Genetics.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.